SNTI News and Press, Senti Biosciences Inc. From 11/08/23

2023-11-08 16:13:08 ET The Allure of Penny Stocks Let’s talk about penny stocks , those underdog shares that could either skyrocket or plummet before you’ve finished your coffee. They’re the ones your friend brags about at parties, boasting about turning poc...

2023-11-08 12:23:00 ET DENVER, Colo., Nov. 8, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Roblox Corp (NYSE: RBLX), The RealReal Inc (NASDAQ: REAL), MSP Recovery Inc (NASDAQ: LIFW), Senti Biosc...

2023-11-07 12:35:09 ET DENVER, Colo., Nov. 7, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; PaxMedica Inc (NASDAQ: PXMD), Olaplex Holdings Inc (NASDAQ: OLPX), Hims & Hers Health Inc (NYSE...

2023-11-07 09:58:32 ET DENVER, Colo., Nov. 7, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; PaxMedica Inc (NASDAQ: PXMD), Olaplex Holdings Inc (NASDAQ: OLPX), Hims & Hers Health Inc (NYSE: HIMS), Th...

2023-11-07 09:36:16 ET DENVER, Colo., Nov 7, 2023 ( www.247marketnews.com )- Senti Biosciences Inc. (NASDAQ: SNTI) stated, after yesterday’s market close, that it entered a new strategic collaboration with Celest Therapeutics, a China-based biotechnology company, for the clinical...

2023-11-06 17:21:40 ET More on Senti Biosciences Seeking Alpha’s Quant Rating on Senti Biosciences Historical earnings data for Senti Biosciences Financial information for Senti Biosciences For further details see: Senti stock soars 175% on Chinese...

– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 2024 – – Senti Bio eligible to receive up to $156 million in milestones and royalties – SOUTH SAN ...

– Two poster presentations highlighting new preclinical data with BlueRock Therapeutics – – Two poster presentations showcasing Senti Bio’s proprietary Gene Circuit platform – SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Senti B...

- Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies - - Abstracts include new preclinical data demonstrating ongoing progress from collaboration with BlueRock Therapeutics and new technology d...

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platfor...